✦ LIBER ✦

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer

✍ Scribed by Braybrooke, J.P; Ranson, M; Manegold, C; Mattson, K; Thatcher, N; Cheverton, P; Sekiguchi, M; Suzuki, M; Oyama, R; Talbot, D.C

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of gemcitabine plus oxali

✍ Cappuzzo, F; Novello, S; De Marinis, F; Franciosi, V; Maur, M; Ceribelli, A; Lor 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 117 KB

P-573 Docetaxel-innotecan doublet chemot

✍ Shamseddine, A.; Abou-Mourad, Y.; Makarem, J.; Kattan, J.; Farhat, F.; Jalloul, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Phase II trial of weekly docetaxel and g

✍ Sujith Kalmadi; Giles McNeill; Mellar Davis; David Peereboom; David Adelstein; T 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 68 KB

Phase II study of weekly paclitaxel as s

✍ Ceresoli, Giovanni Luca; Gregorc, Vanesa; Cordio, Stefano; Bencardino, Katia Bru 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Gemcitabine and vinorelbine as first-lin

✍ E Laack; T Mende; J Benk; A Chemaissani; J Scholtze; C Lorenz; A Niestroy; K Dal 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 144 KB

A phase II multicenter study of combined

✍ Joppert, M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 101 KB